SUN Dermatology is on the rise
SUN Dermatology has launched several products for conditions including acne and actinic keratosis under their branded dermatology business. In addition, SUN Dermatology is also investigating a novel therapeutic approach to psoriasis treatment.1
SUN Dermatology is a division of Sun Pharmaceutical Industries, Inc., which is part of Sun Pharmaceutical Industries, Ltd.—the world’s fifth largest specialty generic pharmaceutical company. Sun Pharmaceuticals provides high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries around the world. The global presence of Sun Pharmaceuticals is supported by 47 manufacturing facilities and R&D centers across 6 continents. Sun Pharmaceuticals fosters excellence through innovation supported by strong R&D capabilities comprising approximately 2,000 scientists and R&D investments of over 7% of annual revenues.1
IL-23 inhibition: Targeting psoriasis at its core2-4
Although current psoriasis therapies have shown improved outcomes compared to older therapeutic agents, inadequate long-term efficacy as well as safety concerns may limit their use.2,5,6 Currently, the development of investigational biologics, which are designed to offer precision targeting of the inflammatory pathway linked to psoriasis through IL-23, may address these unmet needs.5
These research efforts have led to the creation of novel, investigational anti-IL-23p19 monoclonal antibodies designed to precisely target the master cytokine, IL-23, which is now seen as the optimal treatment target in chronic plaque psoriasis.7,8 In clinical trials, positive results with a new molecule validate the important role of IL-23 in moderate-to-severe plaque psoriasis.1,5
The worldwide rights to one of these promising, investigational anti-IL-23p19 molecules were acquired from Merck in 2014 by SUN Dermatology, a division of Sun Pharmaceutical Industries, Inc.1 SUN Dermatology is fully committed to bringing therapeutic innovations to market, including targeted IL-23 inhibition in the treatment of moderate-to-severe plaque psoriasis.
References: 1. Data on file. Sun Pharmaceutical Industries, Inc. 2. Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28(4):179-193. 3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. 4. Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11-27. 5. Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Brit J Dermatol. 2015;173(4):930-939. 6. Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5(1):9-19. 7. Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010;185(10):5688-5691. 8. Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222-226.